Lv5
900 积分 2021-09-15 加入
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
22天前
已完结
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
1个月前
已完结
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
1个月前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
2个月前
已完结
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
2个月前
已完结
A review of HER2 overexpression and somatic mutations in cancers
2个月前
已完结
HER2-targeted therapies beyond breast cancer — an update
2个月前
已完结
A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non–Small-Cell Lung Cancer (NSCLC)
2个月前
已完结
1058P Real world efficacy and safety of continuing anlotinib plus standard-of-care treatment beyond disease progression in patients with advanced non–small cell lung cancer
4个月前
已关闭
1058P Real world efficacy and safety of continuing anlotinib plus standard-of-care treatment beyond disease progression in patients with advanced non–small cell lung cancer
4个月前
已关闭
皖公网安备34019202002308
